Hepatitis C point-of-care diagnostics: in search of a single visit diagnosis

Expert Review of Molecular Diagnostics

Volumn 17, Issue 12, 2017, Pages 1109-1115

  Grebely, Jason ^a   Applegate, Tanya L ^a   Cunningham, Philip ^b   Feld, Jordan J ^c  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b St Vincent's Centre for Applied Medical Research   (Australia)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

diagnostics; HCV; PWID; rapid; RNA; Testing

Indexed keywords

CENTRALIZATION; DRIED BLOOD SPOT TESTING; HEPATITIS C; HUMAN; LABORATORY TEST; LOW INCOME COUNTRY; POINT OF CARE TESTING; PRODUCT DEVELOPMENT; QUALITY CONTROL; REVIEW; GENETICS; HEALTH CARE DELIVERY; HEPACIVIRUS; ISOLATION AND PURIFICATION; PATHOGENICITY; POINT OF CARE SYSTEM;

VIRUS RNA;

HEALTH SERVICES ACCESSIBILITY; HEPACIVIRUS; HEPATITIS C; HUMANS; POINT-OF-CARE SYSTEMS; RNA, VIRAL;

EID: 85034780464     PISSN: 14737159     EISSN: 17448352     Source Type: Journal    
DOI: 10.1080/14737159.2017.1400385     Document Type: Review

References (71)

1. The Polaris Observatory HCV Collaborators. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. Lancet Gastro Hepatol. 2017;2:161–176.
2. Stanaway JD, Flaxman AD, Naghavi M, et al. The global burden of viral hepatitis from 1990 to 2013: findings from the global burden of disease study 2013. Lancet. 2016;388:1081–1088.
3. Dore GJ, Feld JJ., Hepatitis C virus therapeutic development: in pursuit of “perfectovir”. Clin Infect Dis. 2015;60:1829–1836.
4. WHO. Global health sector strategy on viral hepatitis 2016-2021. Geneva, Switzerland: WHO Press. 2017.
5. Schito M, Peter TF, Cavanaugh S, et al. Opportunities and challenges for cost-efficient implementation of new point-of-care diagnostics for HIV and tuberculosis. J Infect Dis. 2012;205 Suppl 2:S169–180.
6. Pant Pai N, Balram B, Shivkumar S, et al. Head-to-head comparison of accuracy of a rapid point-of-care HIV test with oral versus whole-blood specimens: a systematic review and meta-analysis. Lancet Infect Dis. 2012;12:373–380.
7. Drain PK, Hyle EP, Noubary F, et al. Diagnostic point-of-care tests in resource-limited settings. Lancet Infect Dis. 2014;14:239–249.
8. Gliddon HD, Peeling RW, Kamb ML, et al. A systematic review and meta-analysis of studies evaluating the performance and operational characteristics of dual point-of-care tests for HIV and syphilis. Sex Transm Infect. 2017 Jul 26. pii: sextrans-2016-053069. doi: 10.1136/sextrans-2016-053069. [Epub ahead of print].
9. Drobniewski F, Cooke M, Jordan J, et al. Systematic review, meta-analysis and economic modelling of molecular diagnostic tests for antibiotic resistance in tuberculosis. Health Technol Assess. 2015;19:1-188, vii-viii.
10. Causer LM, Hengel B, Natoli L, et al. A field evaluation of a new molecular-based point-of-care test for chlamydia and gonorrhoea in remote Aboriginal health services in Australia. Sex Health. 2015;12:27–33.
11. Natoli L, Maher L, Shephard M, et al. Point-of-care testing for chlamydia and gonorrhoea: implications for clinical practice. PloS One. 2014;9:e100518.
12. Hislop J, Quayyum Z, Flett G, et al. Systematic review of the clinical effectiveness and cost-effectiveness of rapid point-of-care tests for the detection of genital chlamydia infection in women and men. Health Technol Assess. 2010;14:1-97, iii-iv.
13. Causer LM, Kaldor JM, Conway DP, et al. An evaluation of a novel dual treponemal/nontreponemal point-of-care test for syphilis as a tool to distinguish active from past treated infection. Clin Infect Dis. 2015;61:184–191.
14. Watchirs Smith LA, Hillman R, Ward J, et al. Point-of-care tests for the diagnosis of Neisseria gonorrhoeae infection: a systematic review of operational and performance characteristics. Sex Transm Infect. 2013;89:320–326.
15. Yehia BR, Schranz AJ, Umscheid CA, et al. The treatment cascade for chronic hepatitis C virus infection in the United States: a systematic review and meta-analysis. PloS One. 2014;9:e101554.
16. Patel RC, Vellozzi C, Smith BD., Results of hepatitis C birth-cohort testing and linkage to care in selected U.S. Sites, 2012-2014. Public Health Rep. 2016;131 Suppl 2:12–19.
17. Mera J, Vellozzi C, Hariri S, et al. Identification and clinical management of persons with chronic hepatitis C virus infection - cherokee nation, 2012-2015. MMWR Morb Mortal Wkly Rep. 2016;65:461–466.
18. Snow K, Scott N, Clothier HJ, et al. Limited provision of diagnostic services to Victorians living with hepatitis C antibodies, 2001-2012: a multi-level modelling analysis. Aust N Z J Public Health. 2016 Aug 14. doi: 10.1111/1753-6405.12560. [Epub ahead of print].
19. Janjua NZ, Kuo M, Yu A, et al. The population level cascade of care for hepatitis C in British Columbia, Canada: the BC Hepatitis Testers Cohort (BC-HTC). EBioMedicine. 2016;12:189–195.
20. Iversen J, Grebely J, Catlett B, et al. Estimating the cascade of hepatitis C testing, care and treatment among people who inject drugs in Australia. Int J Drug Policy. 2017 Sep;47:77-85.
21. Cox J, Graves L, Marks E, et al. Knowledge, attitudes and behaviours associated with the provision of hepatitis C care by Canadian family physicians. J Viral Hepat. 2011;18:e332–340.
22. Gupta L, Shah S, Ward JE. Educational and health service needs of Australian general practitioners in managing hepatitis C. J Gastroenterol Hepatol. 2006;21:694–699.
23. Shehab TM, Sonnad SS, Lok AS. Management of hepatitis C patients by primary care physicians in the USA: results of a national survey. J Viral Hepat. 2001;8:377–383.
24. Marshall AD, Micallef M, Erratt A, et al. Liver disease knowledge and acceptability of non-invasive liver fibrosis assessment among people who inject drugs in the drug and alcohol setting: the LiveRLife Study. Int J Drug Policy. 2015;26:984–991.
25. Treloar C, Hull P, Dore GJ, et al. Knowledge and barriers associated with assessment and treatment for hepatitis C virus infection among people who inject drugs. Drug Alcohol Rev. 2012;31:918–924.
26. Busch MP. Insights into the epidemiology, natural history and pathogenesis of hepatitis C virus infection from studies of infected donors and blood product recipients. Transfus Clin Biol. 2001;8:200–206.
27. Cox AL, Netski DM, Mosbruger T, et al. Prospective evaluation of community-acquired acute-phase hepatitis C virus infection. Clin Infect Dis. 2005;40:951–958.
28. Shafer K, Pappalardo BL, Tobler LH, et al. Testing strategy to identify cases of acute hepatitis C virus (HCV) infection and to project HCV incidence rates. J Clin Microbiol. 2008;46:499–506.
29. Glynn SA, Wright DJ, Kleinman SH, et al. Dynamics of viremia in early hepatitis C virus infection. Transfusion. 2005;45:994–1002.
30. Chevaliez S, Pawlotsky JM. How to use virological tools for optimal management of chronic hepatitis C. Liver Int. 2009;29 Suppl 1:9–14.
31. Seigneres B, Descamps F, Croise R, et al. Multicenter clinical evaluation of the new 3rd generation assay for detection of antibodies against hepatitis C virus on the VIDAS((R)) system. J Clinical Virology: Official Publication Pan Am Soc Clin Virol. 2016;78:20–26.
32. Gourlain K, Soulier A, Pellegrin B, et al. Dynamic range of hepatitis C virus RNA quantification with the Cobas Ampliprep-Cobas Amplicor HCV Monitor v2.0 assay. J Clin Microbiol. 2005;43:1669–1673.
33. Chevaliez S, Bouvier-Alias M, Pawlotsky JM. Performance of the Abbott real-time PCR assay using m2000sp and m2000rt for hepatitis C virus RNA quantification. J Clin Microbiol. 2009;47:1726–1732.
34. Chevaliez S, Dubernet F, Dauvillier C, et al. The new aptima HCV Quant Dx Real-time TMA Assay Accurately Quantifies Hepatitis C Virus Genotype 1-6 RNA. J Clinical Virology: Official Publication Pan Am Soc Clin Virol. 2017;91:5–11.
35. McHugh MP, Wu AHB, Chevaliez S, et al. Multicenter Evaluation of the Cepheid Xpert Hepatitis C Virus Viral Load Assay. J Clin Microbiol. 2017;55:1550–1556.
36. Pas S, Molenkamp R, Schinkel J, et al. Performance evaluation of the new Roche cobas AmpliPrep/cobas TaqMan HCV test, version 2.0, for detection and quantification of hepatitis C virus RNA. J Clin Microbiol. 2013;51:238–242.
37. Grebely J, Sacks-Davis R, et al. The effects of female sex, viral genotype, and IL28B genotype on spontaneous clearance of acute hepatitis C virus infection. Hepatology. 2014;59:109–120.
38. Micallef JM, Kaldor JM, Dore GJ. Spontaneous viral clearance following acute hepatitis C infection: a systematic review of longitudinal studies. J Viral Hepat. 2006;13:34–41.
39. Freiman JM, Tran TM, Schumacher SG, et al. Hepatitis C core antigen testing for diagnosis of hepatitis C virus infection: a systematic review and meta-analysis. Ann Intern Med. 2016 Sep 6;165(5):345-355.
40. EASL. EASL Recommendations on Treatment of Hepatitis C 2016. J Hepatol. 2017;66:153–194.
41. Easterbrook PJ, Group WHOGD. Who to test and how to test for chronic hepatitis C infection - 2016 WHO testing guidance for low- and middle-income countries. J Hepatol. 2016;65:S46–66.
42. Chevaliez S, Soulier A, Poiteau L, et al. Clinical utility of hepatitis C virus core antigen quantification in patients with chronic hepatitis C. J Clinical Virology: Official Publication Pan Am Soc Clin Virol. 2014;61:145–148.
43. Duchesne L, Njouom R, Lissock F, et al. HCV Ag quantification as a one-step procedure in diagnosing chronic hepatitis C infection in Cameroon: the ANRS 12336 study. J Int AIDS Soc. 2017;20:1–8.
44. Lamoury FMJ, Soker A, Martinez D, et al. Hepatitis C virus core antigen: a simplified treatment monitoring tool, including for post-treatment relapse. J Clinical Virology: Official Publication Pan Am Soc Clin Virol. 2017;92:32–38.
45. Cunningham EB, Applegate TL, Lloyd AR, et al. Mixed HCV infection and reinfection in people who inject drugs–impact on therapy. Nat Rev Gastroenterol Hepatol. 2015;12:218–230.
46. Bouchardeau F, Cantaloube JF, Chevaliez S, et al. Improvement of hepatitis C virus (HCV) genotype determination with the new version of the INNO-LiPA HCV assay. J Clin Microbiol. 2007;45:1140–1145.
47. Chevaliez S, Rodriguez C, Pawlotsky JM. New virologic tools for management of chronic hepatitis B and C. Gastroenterology. 2012;142:1303–1313 e1301.
48. Drobnik A, Judd C, Banach D, et al. Public health implications of rapid hepatitis C screening with an oral swab for community-based organizations serving high-risk populations. Am J Public Health. 2011;101:2151–2155.
49. Jewett A, Smith BD, Garfein RS, et al. Field-based performance of three pre-market rapid hepatitis C virus antibody assays in STAHR (Study to Assess Hepatitis C Risk) among young adults who inject drugs in San Diego, CA. J Clin Virol. 2012;54:213–217.
50. Smith BD, Teshale E, Jewett A, et al. Performance of premarket rapid hepatitis C virus antibody assays in 4 national human immunodeficiency virus behavioral surveillance system sites. Clin Infect Dis. 2011;53:780–786.
51. Smith BD, Drobeniuc J, Jewett A, et al. Evaluation of three rapid screening assays for detection of antibodies to hepatitis C virus. J Infect Dis. 2011;204:825–831.
52. Shivkumar S, Peeling R, Jafari Y, et al. Accuracy of rapid and point-of-care screening tests for hepatitis C: a systematic review and meta-analysis. Ann Intern Med. 2012;157:558–566.
53. Wong VW, Wong GL, Chim AM, et al. Targeted hepatitis C screening among ex-injection drug users in the community. J Gastroenterol Hepatol. 2014 Jan;29(1):116-120.
54. Poiteau L, Soulier A, Rosa I, et al. Performance of rapid diagnostic tests for the detection of antibodies to hepatitis C virus in whole blood collected on dried blood spots. J Viral Hepat. 2016;23:399–401.
55. Chevaliez S, Poiteau L, Rosa I, et al. Prospective assessment of rapid diagnostic tests for the detection of antibodies to hepatitis C virus, a tool for improving access to care. Clin Microbiol Infect. 2016;22:459 e451–456.
56. Soulier A, Poiteau L, Rosa I, et al. Dried blood spots: a tool to ensure broad access to hepatitis C screening, diagnosis, and treatment monitoring. J Infect Dis. 2016;213:1087–1095.
57. Coats JT, Dillon JF. The effect of introducing point-of-care or dried blood spot analysis on the uptake of hepatitis C virus testing in high-risk populations: a systematic review of the literature. ‎Int J Drug Policy. 2015;26:1050–1055.
58. Greenman J, Roberts T, Cohn J, et al. Dried blood spot in the genotyping, quantification and storage of HCV RNA: a systematic literature review. J Viral Hepat. 2015;22:353–361.
59. Grebely J, Lamoury FMJ, Hajarizadeh B, et al. Evaluation of the Xpert HCV Viral Load point-of-care assay from venepuncture-collected and finger-stick capillary whole-blood samples: a cohort study. Lancet Gastroenterol Hepatol. 2017;2:514–520.
60. Day C, White B, Thein H, et al. Experience of hepatitis C testing among injecting drug users in Sydney, Australia. AIDS Care. 2008;20:116–123.
61. Gupta E, Agarwala P, Kumar G, et al. Point -of -care testing (POCT) in molecular diagnostics: performance evaluation of GeneXpert HCV RNA test in diagnosing and monitoring of HCV infection. J Clin Virol. 2017;88:46–51.
62. Bajis S, Dore GJ, Hajarizadeh B, et al. Interventions to enhance testing, linkage to care and treatment uptake for hepatitis C virus infection among people who inject drugs: a systematic review. ‎Int J Drug Policy. 2017 Sep;47:34-46.
63. Meyer JP, Moghimi Y, Marcus R, et al. Evidence-based interventions to enhance assessment, treatment, and adherence in the chronic Hepatitis C care continuum. Int J Drug Policy. 2015;26:922–935.
64. Morano JP, Zelenev A, Lombard A, et al. Strategies for hepatitis C testing and linkage to care for vulnerable populations: point-of-care and standard HCV testing in a mobile medical clinic. J Community Health. 2014;39:922–934.
65. Bottero J, Boyd A, Gozlan J, et al. Simultaneous human immunodeficiency virus-hepatitis B-hepatitis C point-of-care tests improve outcomes in linkage-to-care: results of a randomized control trial in persons without healthcare coverage. Open Forum Infect Dis. 2015;2:ofv162.
66. Beckwith CG, Kurth AE, Bazerman LB, et al. A pilot study of rapid hepatitis C virus testing in the Rhode Island Department of Corrections. J Public Health (Bangkok). 2016;38:130–137.
67. McAllister G, Innes H, McLeod A, et al. Uptake of hepatitis C specialist services and treatment following diagnosis by dried blood spot in Scotland. J Clinical Virology: Official Publication Pan Am Soc Clin Virol. 2014;61:359–364.
68. MSF. Putting HIV and HCV to the Test: A Product Guide for Point-of-care CD4 Tests and Laboratory-based Point-of-care HIV and HCV Viral Load Tests. Geneva, Switzerland: MSF; 2017.
69. Saraswat V, Norris S, De Knegt RJ, et al. Historical epidemiology of hepatitis C virus (HCV) in select countries - volume 2. J Viral Hepat. 2015;22:6–25.
70. Liakina V, Hamid S, Tanaka J, et al. Historical epidemiology of hepatitis C virus (HCV) in select countries - volume 3. J Viral Hepat. 2015;22:4–20.
71. Bruggmann P, Berg T, Ovrehus AL, et al. Historical epidemiology of hepatitis C virus (HCV) in selected countries. J Viral Hepat. 2014;21:5–33.